Keywords: bone marrow transplantation; hepatitis C jects with HCV infection pretransplant vs 59% (51-67%, virus; chronic hepatitis; veno-occlusive disease P = 0.0001) in subjects without HCV infection pretransplant. This difference may reflect persisting abnormal pretransplant liver function, increased hepatic damage in HCV-infected subjects and/or ascertainment biases. For Recently, several studies in this journal and elsewhere have example, it is likely that people with prior hepatitis may discussed the impact of hepatitis C virus (HCV) infection have more frequent liver function tests than others. on the outcome of bone marrow transplants. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14][15] [16] [17] [18] This is an Hepatic veno-occlusive disease (VOD) was reported in important issue because of the high frequency of HCV 14% (4-24%) of subjects with, vs 8% (6-10%, P = 0.2) of infection, mostly from prior transfusions, in potential transsubjects without, pretransplant HCV infection. It should be plant recipients. Case reports of post-transplant liver failure noted that most HCV-infected subjects with VOD originate in people with prior non-A non-B (NANB) presumably from one single series. 16 Liver failure occurred in 12% (1-HCV hepatitis, warned about potential risks. Also, several 23%) of subjects with HCV infection vs 11% (7-15%, studies suggested that the transplant-associated immune P = 0.6) of subjects without pretransplant HCV infection. suppression may alter NANB hepatitis virus infection.
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Another issue is whether a transplant increases the likeliHowever, a critical evaluation of the impact of prior HCV hood of progression to chronic hepatitis in people with preinfection on transplant outcome is difficult because of the transplant HCV-infection. Chronic hepatitis was reported many differences in the incidence of HCV infection, the in 59% (48-70%) of subjects with pretransplant HCV tests to detect HCV infection, 22 the distribution of HCV infection vs 29% (24-34%, P Ͻ 0.0001) of subjects without genotypes in infected populations, 16, 23 the transplant strapretransplant HCV infection. This 59% incidence of tegies, and the diagnostic criteria for acute and chronic chronic hepatitis is similar to the 50 to 70% incidence of hepatitis and/or for liver failure.
12, 13 For example, definitive chronic hepatitis in people with HCV infection not receivdiagnosis of HCV infection in immune compromised subing a bone marrow transplant. 26, 27 jects receiving transfusions requires detection of HCV The follow-up of the published studies is inadequate to RNA; 8, 11, 21, 22, 24, 25 this is rarely tested in transplant studies. assess the long-term impact of HCV infection. However, The conclusion is that it is difficult to known which subsince HCV infection does not adversely effect the survival jects have HCV infection. Another problem is ascribing of people with community acquired infection, 28 it is post-transplant liver function abnormalities to HCV infecunlikely it would effect the long-term survival of those that tion vs (or combined with) other causes of liver failure have undergone a bone marrow transplant. including drugs, radiation toxicity, acute and chronic graftIn summary, although people with pretransplant HCV versus-host disease (GVHD), and infections from other infection have a greater risk of having abnormal liver funchepatotropic viruses (such as cytomegalovirus (CMV) or tion tests and developing chronic hepatitis than those withother infectious agents).
out HCV infection pretransplant, these risks are similar to Table 1 summarizes data on the impact of HCV infection those in HCV-infected individuals without a bone marrow in bone marrow transplant recipients in seven studies. These studies were chosen because they compared posttransplant. Also, the high risk of chronic hepatitis should transplant liver abnormalities in subjects with and without be viewed in the context of the disease for which the trans-HCV infection. Controls in most of these studies are not plant is being considered, for example, an otherwise truly comparable, differing in surveillance for hepatitis, can damage the liver. 
